SygenX, Inc.- an emerging leader in regenerative therapies
SygenX, Inc. is an emerging leader in the growing field of regenerative therapies and healthcare solutions. Our patented APIC A2M isolation therapy, is coupled with the only biomarker diagnostic available in the industry. It’s a powerful 1-2 punch in the orthopedic, spine and veterinary market! A2M is a broad-spectrum protease inhibitor that baits and traps all known factors causing cartilage catabolism found in arthritic joints and painful discs. Our APIC system provides a mechanism to concentrate and isolate A2M 6 times the concentration found naturally occurring in the blood. The biomarker Fibronectin-Aggrecan Complex (FAC) Test is performed pre-injection to determine injection efficacy. It is the only one of its kind in the regenerative space! The APIC system was a recipient of Orthopedics This Week’s 2015 Best New Spine Technology Award Recipient.
Stop by our booth to speak with our experts and gather more information on how you can bring this cutting-edge technology as well as other regenerative options into your practice!
Brands: biomarker, Fibronectin-Aggrecan Complex,regenerative therapies